Aptevo Therapeutics Inc
APVO
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.21M
Close$
$14.79
219.5% upside
Current Fair Value
219.5% upsideUndervalued by 219.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.21 Million |
|---|---|
| Enterprise Value | $109,622.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-87.27 |
| Beta | 1.69 |
| Outstanding Shares | 1,060,678 |
Return
| Return on Equity | -252.38% |
|---|---|
| Return on Assets | -147.25% |
| Return on Invested Capital | -176.13% |
Valuation & Multiples
| P/E Ratio | -0.01 |
|---|---|
| PEG | -0.29 |
| Price to Sales | -4.63 |
| Price to Book Ratio | 0.46 |
| Enterprise Value to Revenue | -0.5 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 40.34 |
| Debt to Equity | 0.38 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-5.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-5.39
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.07%▲ 3.15% |
|---|---|
| Total Invested | $229,654▲ 20.01% |
| Investors Holding | 9▼ 1.00% |
ESG Score
No data
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO6...